Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

Bookmark and Share
Published: 1 Jun 2014
Views: 2914
Prof Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA

At a press conference at ASCO 2014, Prof Sweeney presents the findings of an ECOG-led phase III randomised trial which indicate that adding the chemotherapy drug docetaxel to standard hormone therapy extends survival for men with newly diagnosed hormone-sensitive prostate cancer by roughly 10 months.

Read the article for more.